EFFECTS OF VARIOUS FACTORS ON STEADY-STATE PLASMA-CONCENTRATIONS OF TRAZODONE AND ITS ACTIVE METABOLITE M-CHLOROPHENYLPIPERAZINE

被引:50
作者
ISHIDA, M
OTANI, K
KANEKO, S
OHKUBO, T
OSANAI, T
YASUI, N
MIHARA, K
HIGUCHI, H
SUGAWARA, K
机构
[1] HIROSAKI UNIV HOSP,DEPT NEUROPSYCHIAT,HIROSAKI,AOMORI 036,JAPAN
[2] HIROSAKI UNIV HOSP,DEPT PHARM,HIROSAKI,AOMORI 036,JAPAN
[3] GOSHOGAWARA CITY HOSP,DEPT PHARM,GOSHOGAWARA,JAPAN
[4] AKITA UNIV HOSP,DEPT PSYCHIAT,AKITA,JAPAN
关键词
M-CHLOROPHENYLPIPERAZINE; PLASMA CONCENTRATION; SMOKING; STEADY STATE; TRAZODONE;
D O I
10.1097/00004850-199510030-00002
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Effects of various factors on steady state plasma concentrations of trazodone and its active metabolite m-chlorophenylpiperazine (mCPP) were studied in 43 depressed patients (19 males, 24 females) receiving trazodone 150 mg at bedtime for 1-3 weeks, Sixteen cases were smokers, and 19 cases were also receiving various benzodiazepines. The means (and ranges) of plasma concentrations of trazodone and mCPP, and the mCPP/trazodone ratio were 619 (251-1059) ng/ml, 59 (32-139) ng/ml and 0.100 (0.044-0.219), respectively. Smokers had significantly (p < 0.05) lower plasma concentrations of trazodone and higher mCPP/trazodone ratios than non-smokers, Age, sex and co-administration of benzodiazepines did not affect any plasma concentrations or the mCPP/trazodone ratio, In 11 cases where the dose was increased to 300 mg, neither plasma concentration/dose ratios nor the mCPP/trazodone ratio changed significantly, The present study thus suggests that: (1) there is a large interindividual variation in the metabolism of trazodone; (2) smoking enhances the metabolism, but age, sex and co-administration of benzodiazepines do not affect it; (3) trazodone and mCPP have linear kinetics.
引用
收藏
页码:143 / 146
页数:4
相关论文
共 23 条
[11]  
MAYOL RF, 1994, DRUG METAB DISPOS, V22, P171
[12]   ANALYSIS OF TRAZODONE AND META-CHLOROPHENYLPIPERAZINE IN PLASMA AND BRAIN-TISSUE BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY [J].
MILLER, RL ;
DEVANE, CL .
JOURNAL OF CHROMATOGRAPHY, 1986, 374 (02) :388-393
[13]  
MONTELEONE P, 1989, J CLIN PSYCHOPHARM, V9, P284
[14]   NEW DEPRESSION SCALE DESIGNED TO BE SENSITIVE TO CHANGE [J].
MONTGOMERY, SA ;
ASBERG, M .
BRITISH JOURNAL OF PSYCHIATRY, 1979, 134 (APR) :382-389
[15]   NONLINEAR DESIPRAMINE KINETICS - PREVALENCE AND IMPORTANCE [J].
NELSON, JC ;
JATLOW, PI .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1987, 41 (06) :666-670
[16]   PHARMACOKINETICS OF TRAZODONE DURING MULTIPLE DOSING TO PSYCHIATRIC-PATIENTS [J].
NILSEN, OG ;
DALE, O ;
HUSEBO, B .
PHARMACOLOGY & TOXICOLOGY, 1993, 72 (4-5) :286-289
[17]   HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC DETERMINATION OF TRAZODONE AND 1-M-CHLOROPHENYLPIPERAZINE WITH ULTRAVIOLET AND ELECTROCHEMICAL DETECTOR [J].
OHKUBO, T ;
OSANAI, T ;
SUGAWARA, K ;
ISHIDA, M ;
OTANI, K ;
MIHARA, K ;
YASUI, N .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1995, 47 (04) :340-344
[18]   NO INTERACTION OF DIAZEPAM ON AMITRIPTYLINE DISPOSITION IN DEPRESSED-PATIENTS [J].
OTANI, K ;
NORDIN, C ;
BERTILSSON, L .
THERAPEUTIC DRUG MONITORING, 1987, 9 (01) :120-122
[19]   STEADY-STATE PLASMA-CONCENTRATIONS OF MIANSERIN AND ITS MAJOR ACTIVE METABOLITE, DESMETHYLMIANSERIN [J].
OTANI, K ;
SASA, H ;
KANEKO, S ;
KONDO, T ;
FUKUSHIMA, Y .
THERAPEUTIC DRUG MONITORING, 1993, 15 (02) :113-117
[20]   INHIBITION BY FLUOXETINE OF CYTOCHROME-P450 2D6 ACTIVITY [J].
OTTON, SV ;
WU, DF ;
JOFFE, RT ;
CHEUNG, SW ;
SELLERS, EM .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1993, 53 (04) :401-409